Landmark trial evaluates chemotherapy benefit in high-risk early-stage breast cancer
The addition of CDK4/6 inhibitors to endocrine therapy has changed the standard of care for patients with high-risk, early-stage estrogen receptor-positive, HER2-negative (ER+/HER2-) breast cancer by reducing the risk of recurrence. However, one patient subgroup continues to present a clinical dilemma. In current practice, patients with low genomic risk but high anatomic risk receive adjuvant…
Read original article on Medical Xpress - latest medical and health news stories →Related news
-
IBD not linked to risk of hypertensive disorders of pregnancy overall
-
FDA panel narrowly backs multi-cancer blood test despite doubts it works
-
Blood proteins shift during Alzheimer's treatment and may help monitor the effects of the medication
-
Human crying catches dogs’ attention across homes, shelters, and streets
-
COVID-19 pandemic drove violence and moral suffering for nurses in Latin America
-
Chronic pain after cesarean delivery linked to poorer quality of life for months and years after giving birth
-
Risk of death rises with rate of overcrowding, corridor care in hospital emergency department
-
New ambulance triage method could reduce emergency visits for chest pain